biotech · Clostridium Difficile Infection · Autism Spectrum Disorder · FNCHQ
Finch Therapeutics Group
Finch Therapeutics Group clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Somerville, USA
- Employees
- 15
- Programs
- 5
- Drugs
- 2
- Patents
- 33
Finch Therapeutics Group projects
5 ClinicalTrials.gov programs sponsored by Finch Therapeutics Group.
Finch Therapeutics Group has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CP101
Finch Therapeutics Group
Recurrent C. Difficile Infection
1 trial -
CP101
Finch Therapeutics Group
Autism Spectrum Disorder
1 trial -
CP101
Finch Therapeutics Group
Clostridium Difficile Infection
1 trial -
Full Spectrum Microbiota
Finch Therapeutics Group
Clostridium Difficile Infection Recurrence
1 trial -
Fecal Microbiota Transplantation
Finch Therapeutics Group
Enterobacteriaceae Infections
1 trial
Frequently asked questions
How many clinical projects does Finch Therapeutics Group have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.